Retension Pharmaceuticals (NASDAQ:RTSN) Stock Rated Outperform in New Coverage at Oppenheimer

Oppenheimer began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a report issued on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $50.00 price objective on the stock.

Separately, Guggenheim began coverage on shares of Retension Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $55.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $52.50.

Retension Pharmaceuticals Stock Performance

RTSN opened at $10.72 on Tuesday. Retension Pharmaceuticals has a 52-week low of $9.66 and a 52-week high of $18.64.

Insider Activity at Retension Pharmaceuticals

In other Retension Pharmaceuticals news, Director Franklin Berger bought 10,000 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $120,000.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $120,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Keller acquired 20,800 shares of Retension Pharmaceuticals stock in a transaction on Tuesday, October 13th. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the purchase, the chief executive officer owned 423,377 shares of the company’s stock, valued at approximately $5,080,524. This represents a 5.17% increase in their position. The SEC filing for this purchase provides additional information.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.